Bomedemstat ditosylate

Research use only, not for human use.

Bomedemstat ditosylate (IMG-7289 ditosylate) is an orally active lysine-specific demethylase 1 (LSD1) inhibitor with antitumor activity that potentiates the response to PD-1 inhibition in a homozygous model of SCLC, inhibits cancer cell proliferation, and induces apoptosis.

Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis.

Bomedemstat selectively inhibits proliferation and induces apoptosis of Jak2V617F cells by concomitantly increasing expression and methylation of p53.Bomedemstat (50 nM-1 μM; 96 h) enhances survival, induces apoptosis via BCL-XL and PUMA in a TP53-dependent manner, and leads to cell cycle arrest.Apoptosis AnalysisCell Line:SET-2 cells Concentration:50?nM, 100?nM, and 1?μM Incubation Time:96 hours Result:Decreased levels of the antiapoptotic protein BCL-XL and increased levels of the pro-apoptotic protein PUMA.

Bomedemstat treatment (oral gavage; 45?mg/kg; once daily; 56 d) normalizes or improves blood cell counts, reduces spleen volumes, restores normal splenic architecture, and reduces bone marrow fibrosis.Animal Model:Mx-Jak2V617F miceDosage:45?mg/kg Administration:Oral gavage; 45?mg/kg; once daily; 56 days Result:Reduced splenomegaly significantly with a few treated mice normalizing their spleen weight, the 56-day course led to partial restoration of lymph follicles and spleen architecture by histological examination.

——

Apoptosis

Apoptosis

Apoptosis | Histone Demethylase

——

——

1990504-72-7

864.02

C42H50FN7O8S2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (115.74 mM; Ultrasonic )

Cc1ccc(cc1)S(O)(=O)=O.Cc1ccc(cc1)S(O)(=O)=O.[H][C@]1(C[C@H]1NCCC[C@H](NC(=O)c1ccc(cc1)-n1ccnn1)C(=O)N1CCN(C)CC1)c1ccc(F)cc1

——

(-20℃)

With Ice Pack

≥ 2 years